Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma; a Prospective, Single-arm, Open Label, Multicenter Phase II Study: HOMIE-166.

NCT05451862 is registered in ClinicalTrials.gov with Terumo Europe N.V. as lead sponsor.

NCT NCT05451862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05451862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma; a Prospective, Single-arm, Open Label, Multicenter Phase II Study: HOMIE-166.
Lead sponsor
Terumo Europe N.V.
Phase
Not applicable
Overall status
Terminated
Start date
August 21, 2023
Completion date
May 27, 2025
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma